Racecadotril
drugOn this page
Also known as AcetorphanHidrasecNSC-759828RacecadotriloTiorfanTiorfixSID174006909C0164552
Summary
Racecadotril (CHEMBL2103772) is an approved small molecule (ATC A07XA04); indicated across 2 conditions including diarrheal disease and infantile diarrhea.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A07XA04
- Indications: 2 conditions
- Clinical trials: 11
- Chemistry: 385.5 Da · C21H23NO4S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2103772 |
| Name | Racecadotril |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 107751 |
| ATC | A07XA04 |
| Molecular formula | C21H23NO4S |
| Molecular weight | 385.5 |
| InChIKey | ODUOJXZPIYUATO-UHFFFAOYSA-N |
SMILES: CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2
IUPAC name: benzyl 2-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate
Also known as: Acetorphan, Hidrasec, NSC-759828, Racecadotril, Racecadotrilo, Tiorfan, Tiorfix, racecadotril, SID174006909, RACECADOTRIL, C0164552
Patent coverage: 460 distinct patent families (1,787 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Retinoic acid receptor gamma, Glucocorticoid receptor, Cannabinoid receptor 1, Kappa-type opioid receptor, Peroxisome proliferator-activated receptor alpha, Oxysterols receptor LXR-alpha, Nuclear receptor subfamily 1 group I member 2, Voltage-dependent L-type calcium channel subunit alpha-1C, Oxysterols receptor LXR-beta, Nuclear receptor subfamily 1 group I member 3.
Bioactivity
ChEMBL activities: 5 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NR1H2 | 5.22 | AC50 | 6000 | nM | CHEMBL_ACT_25202383 |
| NR3C1 | 5.2 | AC50 | 6300 | nM | CHEMBL_ACT_25116094 |
| NR1I2 | 5.16 | AC50 | 7000 | nM | CHEMBL_ACT_25224659 |
| OPRK1 | 5.07 | AC50 | 8598 | nM | CHEMBL_ACT_25130031 |
| RARG | 5.02 | AC50 | 9500 | nM | CHEMBL_ACT_25211942 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diarrheal disease | 3 | MONDO:0001673 | HP:0002014 |
| infantile diarrhea | 3 | MONDO:0043555 | EFO:1001306 |
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 4 |
| Not specified | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01577043 | PHASE4 | COMPLETED | Efficacy of Racecadotril in Acute Watery Diarrhea in Children |
| NCT01153854 | PHASE3 | COMPLETED | Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico |
| NCT06529497 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Racecadotril Versus Standard Treatment in Decreasing the Duration of Acute Diarrhoea in Children |
| NCT07454421 | PHASE1/PHASE2 | ENROLLING_BY_INVITATION | Racecadotril for Organ Injury in Sepsis Patients |
| NCT01302093 | PHASE1 | COMPLETED | Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults |
| NCT01476683 | PHASE1 | COMPLETED | Study to Compare the Pharmacokinetics Profiles of Four Racecadotril Products |
| NCT01948011 | PHASE1 | COMPLETED | Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules |
| NCT05216822 | PHASE1 | COMPLETED | Anti-Secretory Drug in Treatment of Acute Watery Diarrhea |
| NCT05600062 | Not specified | ACTIVE_NOT_RECRUITING | Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) |
| NCT04885049 | Not specified | UNKNOWN | Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children |
| NCT07392931 | Not specified | COMPLETED | Safety and Efficacy of Racecadotril in Children With Acute Watery Diarrhea |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: diarrheal disease, infantile diarrhea